FDA Approves Sanofi’s Follow-On Insulin
The approval for Admelog (insulin lispro injection) marks the first short-acting insulin approved as a “follow-on” product.
On Dec. 11, 2017, FDA approved Admelog (insulin lispro injection), a short-acting insulin manufactured by Sanofi that is indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with Type 1 diabetes mellitus and adults with Type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product, according to the agency. The drug received tentative approval from FDA on Sep. 1, 2017 and is now being granted final approval.
Admelog is a rapid-acting insulin similar to Eli Lilly and Company’s Humalog, (insulin lispro 100 units/mL), which was approved by FDA in 1996. Lilly’s Humalog is one of the company’s top-selling drugs with 2016 sales of approximately $1.69 billion.
Admelog was approved by FDA through the 505(b)(2) pathway, an abbreviated approval pathway under the Federal Food, Drug, and Cosmetic Act. It was previously granted marketing authorization as a biosimilar, under the proprietary name, Insulin lispro Sanofi, by the European Commission in July 2017.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
